FINPEDMED / NORDICPEDMED aim to increase public awareness about the pediatric drug / medical device development and pediatric clinical trials in Finland and in other Nordic Countries. This can be promoted by publishing some basic information of the Service Requests submitted to FINPEDMED / NORDICPEDMED. Service Requests are preliminary inquiries of possible new trials OR proposed expert consultations, both addressed for the clinical trial feasibility evaluation, or for the medical / scientific assessment.
Service Request´s public information is listed on a table below. You may open each request and look for the details by clicking the bar arrow beside the number. Service Request category C includes Consultations and category R includes Basic feasibility assessment for a new clinical trial.
- R3561-250: left ventricular systolic dysfunction (LVSD)
- R3561-249: Atopic Dermatitis
- R3561-248: Vitiligo
- R3561-247: Recurrent/Refractory Solid Tumors
- R3561-245: Asthma
- R3561-243: Chronic Graft Versus Host Disease (cGVHD).
- R3561-242: Cow Milk Protein Allergy
- C3561-78: Lipodystrophy
- C3561-76: XLH
- C3561-75: Aicardi Goutières Syndrome
- R3561-241: Arginase 1 deficiency
- R3561-233: Batten CLN3 disease
- C3561-71: Alpha-1 antitrypsin deficiency (AATD)
- C3561-70: Epilepsy: focal and idiopathic epilepsy.
- C3561-69: Wilson Disease
- R3561-231: RSV
- R3561-230: acute pouchitis
- R3561-228: Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS)
- R3561-227: Moderately to severely active Ulcerative colitis or Crohn’s disease
- R3561-226: Herpes Zoster
- R3561-225: Congenital Hyperinsulinism
- R3561-224: Chronic and episodic migraine
- R3561-223: Duchenne Muscular Dystrophy
- R3561-222: Adolescents and children with anemia associated with chronic kidney disease.
- R3561-221: eosinophilic esophagitis
- R3561-220: Insomnia Disorder
- R3561-218: Type 1 Diabetes
- R3561-217: moderate-to-severe atomic dermatitis (AD)
- R3561-216: Asthma
- R3561-215: ADHD
- R3561-214: Kindney transplant recipient
- R3561-213: heart failure due to left ventricular systolic dysfunction
- R3561-212: migraine
- R3561-209: Crohn’s Disease (CD) and Ulcerative Colitis (UC)
- C3561-67: metakromaattinen leukodystrofia (MLD)
- R3561-208: pediatric patients with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas receiving selumetinib
- C3561-66: Alfa-mannosidosis and LHON
- C3561-65: Renal complement-mediated diseases
- R3561-207: NLRC4 Gain of Function
- R3561-206: Insomnia disease
- C3561-64: Nephropatic cystinosis
- C3561-63: Insomnia disorder
- C3561-62: Bardet Biedl Syndrome; Alström Syndrome
- R3561-205: SMA type 2 and type 3a (treatment naive)
- C3561-61: Metachromatic leukodystrophy (MLD)
- R3561-204: hypereosinophilic syndrome
- R3561-203: Neurofibromatosis Type 1 and Plexiform Neurofibromas
- R3561-202: Hemophilia
- R3561-201: Pruritis in adolescents on haemodialysis
- C3561-60: NASH
- R3561-200: Migraine
- R3561-198: Peanut allergy
- C3561-59: cyanotic congenital heart disease (CHD)
- C3561-58: Obesity
- R3561-197: neonatal critical care
- C3561-57: Chronic kidney disease
- R3561-196: Asthma
- R3561-195: MS-disease
- R3561-194: Juvenile PsA
- R3561-193: Atopic Dermatitis
- R3561-192: Familial hypercholesterolemia
- C3561-55: Pediatric ALL
- R3561-188: pulmonary arterial hypertension
- R3561-187: Duschenne Muscular Dystrophy (DMD)
- R3561-186: Spinal Muscular Atrophy
- R3561-185: Spinal Muscular Atrophy
- R3561-184: ILD
- R3561-183: DMD patients with deletion amenable to Exon 51skipping
- R3561-181: Episodic and/or Chronic Migraine
- R3561-180: Mucopolysaccharidoses (MPS), type IV
- R3561-176: Hypoparathyroidism
- R3561-175: Influenza
- C3561-54: Psoriasis
- R3561-174: Epilepsy
- R3561-173: CML and other leukemias, lymphoma, solid tumors
- R3561-172: Duchenne Muscular Dystrophy
- R3561-171: Retinopathy of prematurity
- R3561-170: Pediatric Participants (ages 10 to 17 years, inclusive) with Type 2 Diabetes Mellitus
- R3561-168: New onset T1DM
- C3561-53: schizophrenia
- R3561-165: Venous thromboembolic event
- C3561-52: AGU
- C3561-51: AGU patients
- R3561-162: Heterozygous Familial Hypercholesterolemia
- R3561-160: SMA (Spinal Muscular Atrophy) TYPE 2 and TYPE 3
- C3561-50: Type 1 spinal muscular atrophy
- R3561-159: Homozygous familial hypersholesterolemia
- R3561-157: Type 2 diabetes
- C3561-49: heterozygous familial hypercholesterolemia (children and adolescents)
- C3561-48: severe ulcerative colitis (US) or Crohn’s disease (CD).
- C3561-47: Cystic Fibrosis
- R3561-156: Pediatric Atopic Dermatitis
- R3561-155: Type II Diabetes
- R3561-154: Respiratory Syncytial Virus
- R3561-153: Psoriatic and enthesitis-related arthritis JIA subtypes
- C3561-46: Cystic Fibrosis
- R3561-152: Pulmonary Arterial Hypertension (PAH)
- R3561-151: Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
- R3561-150: Glucocorticoid induced Osteoporisis
- R3561-149: recurrent pediatric clostridium difficile infections
- R3561-148: Type 2 diabetes mellitus 10 -17 years old
- R3561-147: venous thromboembolism
- C3561-45: prohlylaxis of thrombotic complications in children born with a single ventricle
- C3561-44: Crohn´s disease
- R3561-146: Major Depressive Disorder (MDD)
- C3561-43: Juvenile idiopathic arthritis
- R3561-143: secondary thrombocytopenia
- C3561-42: MDD (major depression disorder)
- R3561-142: Persistent asthma on ICS/LABA treatment
- R3561-141: Diebetes Mellitus type 1
- R3561-140: Intravascular Procedures For Congenital Heart Disease
- C3561-41: Children with persistent asthma
- C3561-40: Paediatric Melanoma / Lymphoma
- R3561-139: Repeated seizures
- C3561-39: Single-dose study of oral rivaroxaban dry powder suspension formulation in children treated for thrombosis
- R3561-138: Pediatric Treatment of VTE with rivaroxaban
- R3561-137: Pediatric Treatment of VTE with rivaroxaban
- C3561-37: Type 1 Diabetes Mellitus
- R3561-136: MDD
- R3561-133: Atopic Dermatitis
- R3561-132: Heterozygous Familiar Hypercholesterolemia
- R3561-131: neutropenia or expected neutropenia
- R3561-130: Prevention of Chemotherapy-Induced Nausea and Vomiting
- C3561-36:
- C3561-35:
- C3561-34:
- R3561-129: euvolemic or hypervolemic hyponatremia
- R3561-127: B-precursor ALL
- R3561-126: pediatric type 2 diabetes
- C3561-33:
- R3561-125: Epilepsy
- R3561-113: Opioid induced constipation